- New RINVOQ (upadacitinib) analysis from the pivotal Phase 3 atopic dermatitis clinical program shows consistent EASI 75 rates for RINVOQ across key baseline characteristics of adults and adolescents with moderate to severe atopic dermatitis at week 16[1]

- Analysis from the Heads Up study shows more patients treated with RINVOQ 30 mg achieved EASI 75 at week 16 compared to dupilumab in four body regions (head and neck, trunk, upper limbs and lower limbs) of adults with moderate to severe atopic dermatitis[2]

- Late-breaking presentation of an open-label extension trial following Heads Up shows switching from dupilumab to RINVOQ 30 mg resulted in high rates of skin clearance and itch reduction after 16 weeks of RINVOQ therapy[3]

- No new safety risks were observed compared to previously reported results from RINVOQ atopic dermatitis studies[1-6]

NORTH CHICAGO, Ill., Sept. 30, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new analyses from the Phase 3 RINVOQ® (upadacitinib) atopic dermatitis clinical trial program to be presented at the 30th European Academy of Dermatology and Venereology (EADV) Virtual Congress. One analysis showed a greater proportion of patients treated with RINVOQ (15 mg or 30 mg; once daily) with or without topical corticosteroids achieved 75 percent improvement in the Eczema Area Severity Index (EASI 75) at week 16 compared to placebo, regardless of age, sex, race, weight, disease severity and previous exposure to systemic therapy.1 An additional analysis showed more patients treated with RINVOQ 30 mg achieved EASI 75 at week 16 compared to dupilumab when measured in four body regions.2

"These data further highlight RINVOQ's potential to help alleviate the itch and rash in moderate to severe atopic dermatitis, offering additional support of its efficacy across various patient characteristics and areas of the body," said Thomas Hudson, M.D., senior vice president, research and development, chief scientific officer, AbbVie. "Advancing research and fostering innovation remain at the heart of our efforts to help transform care for atopic dermatitis patients, many of whom still suffer from the unrelenting symptoms of the disease despite available treatment options."

P0183: Efficacy of Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Stratified Analysis from Three Phase 3 Trials by Key Baseline Characteristics: Study HighlightsIn this study, investigators presented results evaluating whether RINVOQ efficacy observed in the global Phase 3 clinical trials (Measure Up 1, Measure Up 2 and AD Up) differed based on age, weight, sex, disease severity, race/ethnicity and previous treatment history.1 The analysis observed that for the 15 mg and 30 mg treatment groups, the percentage of patients achieving the primary endpoint of EASI 75 at week 16 across the subgroups was consistent with that observed in the overall study population.1 More than half of all patients for all subgroups (more than 51 percent, nominal p